Full Text View
Tabular View
No Study Results Posted
Related Studies
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
This study has been completed.
Study NCT00017199   Information provided by National Cancer Institute (NCI)

First Received on June 6, 2001.   Last Updated on January 30, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Additional conditions recognized in this trial
Adenoma, Islet Cell
Carcinoid Tumor
Gastrointestinal Neoplasms
Malignant Carcinoid Syndrome
Neuroendocrine Tumors
More general conditions related to this trial
Adenocarcinoma
Adenoma
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Pancreatic Diseases
Pancreatic Neoplasms
Interventions listed in this trial
bortezomib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services